Observational studyNature medicine2024
Magnesium-ibogaine therapy in veterans with traumatic brain injuries.
Observational study in Nature medicine, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 36 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
36 citing papers in PubMed, 53 citations in OpenAlex.
- Nanozyme-based therapeutic strategies for traumatic brain injury.International journal of pharmaceutics: X · 2026Review
- Adverse Health Outcomes of Psilocybin, LSD, MDMA, Ibogaine, and 5-MeO-DMT.JAMA network open · 2026Article
- The Emerging Neurobiology of Psychedelics: Critical Periods, Metaplasticity, and Extracellular Matrix Remodeling.Annual review of neuroscience · 2026Review
- The intersection between psychedelics and schizophrenia spectrum disorders: Reevaluating risk and therapeutic potential.Journal of psychopharmacology (Oxford, England) · 2026Review
- Rare but relevant: Ibogaine and cardiovascular complications-prolonged QT interval and ventricular arrhythmias.Addiction (Abingdon, England) · 2026Review
- Ibogaine induces juvenile-like plasticity and modulates functional and structural regulators of plasticity in the adult mouse visual cortex.BMC neuroscience · 2026Article
- Psychedelics and Autism Therapy: A Review of Current Research and Future Directions.Current issues in molecular biology · 2026Review
- Existing and Potential Therapies for Post-Traumatic Stress Disorder and Persistent Post-Concussion Symptoms in Intimate Partner Violence: A Narrative Review.Brain sciences · 2026Review
- Article
- Article
- Neurorestorative properties of ibogaine: linking multi-receptor affinities to remyelination and metabolic restoration.Acta neuropsychiatrica · 2026Review
- The science of psychedelic medicine.Nature medicine · 2026Review
- Accelerated recovery using magnesium ibogaine: characterizing the subjective experience of its rapid healing from neuropsychiatric disorders.Npj mental health research · 2026Article
- Psychedelic therapeutics in psychiatric conditions.Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology · 2026Review
- Deciphering Ibogaine's Matrix Pharmacology: Multiple Transporter Modulation at Serotonin Synapses.Journal of the American Chemical Society · 2026Article
- Sustained abstinence in severe ketamine use disorder following ibogaine treatment case report.Frontiers in psychiatry · 2026Article
- Exploring the potential of psychedelics in brain injury recovery: a thematic analysis of participant narratives.Frontiers in neurology · 2026Article
- Clinical improvement following an integrative iboga microdosing protocol in post-concussive and hypoxic brain injury syndromes: a case series.Frontiers in pharmacology · 2026Article
- Effect of early intravenous magnesium sulfate on clinical outcomes in patients with moderate to severe traumatic brain injury: a study protocol for a randomized controlled trial.Frontiers in medicine · 2026Article
- Psychedelic therapy: a paradigm shift in treating neuropsychiatric disorders.Science China. Life sciences · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
20 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Traumatic brain injury (TBI) is a leading cause of disability. Sequelae can include functional impairments and psychiatric syndromes such as post-traumatic stress disorder (PTSD), depression and anxiety. Special Operations Forces (SOF) veterans (SOVs) may be at an elevated risk for these complications, leading some to seek underexplored treatment alternatives such as the oneirogen ibogaine, a plant-derived compound known to interact with multiple neurotransmitter systems that has been studied primarily as a treatment for substance use disorders. Ibogaine has been associated with instances of fatal cardiac arrhythmia, but coadministration of magnesium may mitigate this concern. In the present study, we report a prospective observational study of the Magnesium-Ibogaine: the Stanford Traumatic Injury to the CNS protocol (MISTIC), provided together with complementary treatment modalities, in 30 male SOVs with predominantly mild TBI. We assessed changes in the World Health Organization Disability Assessment Schedule from baseline to immediately (primary outcome) and 1 month (secondary outcome) after treatment. Additional secondary outcomes included changes in PTSD (Clinician-Administered PTSD Scale for DSM-5), depression (Montgomery-Åsberg Depression Rating Scale) and anxiety (Hamilton Anxiety Rating Scale). MISTIC resulted in significant improvements in functioning both immediately (P
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.